Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

666.26 +3.38 (+0.51%)
Streaming Delayed Price Updated: 2:57 PM EDT, Jul 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool
News headline image
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗
It might pull it off, provided several things fall right in place. 
Via The Motley Fool
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals ↗
Via Chartmill
Unusual volume S&P500 stocks in Monday's session ↗
Via Chartmill
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗
Parabilis Medicines is ambitious, but it has Regeneron on its side already. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
2 Underrated Weight Loss Stocks to Buy and Hold ↗
They look well-positioned to grab a slice of the fast-growing anti-obesity market. 
Via The Motley Fool
News headline image
This Stock Is Up 58% This Year. Is It too Late to Buy? ↗
There could be additional catalysts for this drugmaker over the next year. 
Via The Motley Fool
News headline image
3 Profitable Stocks We Think Twice About
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy ... 
Via StockStory
News headline image
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
3 Nasdaq 100 Stocks We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares 
Via MarketBeat
News headline image
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron
Check out the companies making headlines this week: Toll Brothers (NYSE:TOL): Homebuilding company Toll Brothers (NYSE:TOL) rose by 8.3% on Wednesday after t... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock with Solid Fundamentals and 2 We Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
Topics Supply Chain
News headline image
Why Regeneron (REGN) Shares Are Trading Lower Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet t... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
3 Reasons to Sell REGN and 1 Stock to Buy Instead
Regeneron has been treading water for the past six months, recording a small return of 3.4% while holding steady at $717.22. The stock also fell short of the... 
Via StockStory
News headline image
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. ↗
The competition is far behind. 
Via The Motley Fool
News headline image
Is This Biotech Stock a Buy After a Groundbreaking Approval? ↗
This milestone came with an asterisk. 
Via The Motley Fool
News headline image
5 Must-Read Analyst Questions From Regeneron’s Q1 Earnings Call
Regeneron's first quarter performance delivered revenue and non-GAAP earnings per share above Wall Street expectations, as management cited strong commercial... 
Via StockStory
Topics Earnings
News headline image
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? ↗
Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment. 
Via The Motley Fool
News headline image
1 Cash-Producing Stock Worth Investigating and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings ↗
Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q1 earnings and a $3B share buyback. Analysts have mixed views on the stock. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.